Within the training cohort of GBM patients from the TCGA, the nomogram and PRSM were constructed based on the combination of Loxl1 and clinicopathological parameters, including age, IDH mutation status, chemotherapy, and radiotherapy (Fig. 5A). This evidence concerns the gene LOXL1 and glioblastoma.